Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunocore Holdings plc - American Depositary Shares (NQ:IMCR)

33.01 +0.34 (+1.04%)
Streaming Delayed Price Updated: 12:15 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunocore Holdings plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
Immunocore (IMCR) Q2 Revenue Jumps 30%
Via The Motley Fool
Topics Earnings Intellectual Property
Immunocore Holdings PLC (NASDAQ:IMCR) Beats Q2 2025 Revenue and EPS Estimates with Strong KIMMTRAK Sales Growth
Immunocore (IMCR) beat Q2 2025 estimates with $98M revenue (+30% YoY) and a narrower EPS loss. KIMMTRAK sales surged 32%, while pipeline progress and strong cash position ($882.8M) boosted investor... 
Via Chartmill
Immunocore reports second quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025
From Immunocore Holdings plc
Via GlobeNewswire
Demystifying Immunocore Holdings: Insights From 9 Analyst Reviews
 
Via Benzinga
Immunocore to present at the 2025 Jefferies Global Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore reports first quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Analyst Expectations For Immunocore Holdings's Future
 
Via Benzinga
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
What Analysts Are Saying About Immunocore Hldgs Stock
 
Via Benzinga
Earnings Scheduled For February 26, 2025
 
Via Benzinga
Analyst Expectations For Immunocore Hldgs's Future
 
Via Benzinga
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
Navigating 8 Analyst Ratings For Immunocore Hldgs
 
Via Benzinga
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers
From Immunocore Holdings plc
Via GlobeNewswire
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?
Morgan Stanley downgrades Amicus Therapeutics, Immunocore, and Immuneering, citing pricing challenges, pipeline updates, and cautious growth outlooks. 
Via Benzinga
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma
From Immunocore Holdings plc
Via GlobeNewswire
3 Fast-Growing Stocks Analysts See Doubling in Price
Clinical-stage biotech firms often have massive upside potential, but much of that possible success hinges on successful trials and product launches. 
Via MarketBeat
Immunocore to present at upcoming investor conferences
From Immunocore Holdings plc
Via GlobeNewswire
Immunocore reports third quarter financial results and provides a business update
From Immunocore Holdings plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.